γ δ T cells were first identified as a novel T-cell subset in the 1980s. 1 Whereas the vast majority of T cells express a T-cell receptor (TCR) composed of αβ heterodimers, a smaller population expresses a γδ TCR. Unlike conventional αβ T cells, γδ T cells are considered to be a unique and conserved subset of T cells cross-linking innate immunity and adaptive immunity. 2 Therefore, γδ T cells are usually categorized as innate immune T cells.
The classification of γδ T cells in murine and human differs. Murine γδ T cells are classified into subtypes depending on the γ chain. Unlike their murine counterparts, human γδ T cells are usually sub-divided based on two variable regions of TCRδ: Vδ1 and Vδ2. Vδ1 cells are the predominant subset found at mucosal surfaces, whereas Vδ2 cells (which are almost exclusively Vγ9 cells) mostly dominate the peripheral blood. In this paper, we mainly focus on human γδ T cells.
There are several key properties that may collectively distinguish human γδ T cells from αβ T cells and thereby define their unique contributions to lymphocyte biology. First, similar to αβ T cells, γδ T cells mostly develop in the thymus, generating their defining γδ TCR via recombination-activating genemediated V(D)J recombination. However, γδ T cells exhibit considerably less TCR diversity than αβ T cells, 3 are thought to undergo maturation much earlier, and play a crucial role in infancy. Second, in contrast to αβ T cells, human γδ T cells account for only 1-5% of the T-cell population in peripheral blood, but these cells are particularly enriched at epithelial surfaces. Third, human γδ T cells appear to respond to a variety of self and foreign, small and large, and peptidic and non-peptidic molecules in a major histocompatibility complexindependent manner. 4 Without positive and negative selection in the thymus, γδ TCRs can directly recognize ectopically expressed intracellular self proteins that signal potential danger or cellular stress. The antigen recognition pattern of γδ TCR is still under investigation; however, a direct antigen-γδ TCR interaction for protein ligands seems to be certain. In recent years, a series of studies indicated a hypothetical mechanism for γδ T-cell antigen recognition patterns in which ectopically expressed intracellular proteins serve as danger signals and trigger the activation of human γδ T cells under stress conditions. [5] [6] [7] The biological functions of human γδ T cells are achieved by secreting cytokines, such as IFN-γ, TNF-α, IL-2 and IL-17, and by exerting direct cytotoxicity to target cells. However, γδ T cells can also display a broad functional phenotype similar to the conventional T helper (Th) 1, Th2, Th17, regulatory T (Treg) cell, follicular helper T (Tfh) cell and cytotoxic T lymphocyte (CTL) subsets, depending on environmental conditions (Figure 1a) . 8 In addition, γδ T cells play important roles both in the host's resistance to exogenous infection and in immune surveillance; γδ T cells initiate a protective immune response to endogenous stress, which is associated with tumorigenesis. 9 The tumor immune microenvironment contributes to tumor initiation, progression, and response to therapy. Innate-like γδ T cells play a particular role among the immune cell subsets in the tumor microenvironment; however, various conflicting functions have been ascribed. 10 It has been confirmed in vitro that human γδ T cells secrete IFN-γ and TNF-α; moreover, human γδ T cells play a cytolytic role against a broad range of tumors, including lymphoma, myeloma, and melanoma, as well as breast, colon, lung, ovary and prostate cancer. Therefore, it has been believed for a long time that tumor-infiltrating γδ T cells are a good prognostic marker in cancer because they display anti-tumor activities similar to Th1 and CTLs. However, the notion has recently been challenged by studies demonstrating that the presence of these cells in the tumor tissue is associated with poor prognosis. 11 Recent studies have demonstrated that signals from the tumor microenvironment, particularly cytokines, can confer some plasticity to γδ T cells and can promote their differentiation into regulatory γδ T cells. 12 In addition to classical CD4 + Treg cells expressing the transcription factor fork head box P3 (FoxP3), the emergence of regulatory γδ T-cell subsets has deepened our understanding of the role of lymphocytes in the maintenance of tolerance. As early as 2011, we reported a novel function of human γδ T cells as regulatory cells by detecting their suppressive effect on the proliferation of autologous naive CD4 + T cells. 13 These regulatory γδ T cells also expressed FoxP3 and could be generated in vitro by stimulation with anti-γδTCR in the presence of TGF-β and IL-2; the regulatory γδ T cells primarily belonged to the Vδ1 subset with a CD27 + CD25 high phenotype. Other studies also demonstrated the acquired regulatory function of γδ T cells when exposed to TGF-β. 14, 15 In addition to TGF-β, we have recently found that IL-4 has a similar ability to induce regulatory γδ T cells. 16 IL-4 promotes regulatory Vδ1 T cells via IL-10 production and inhibits the function of Vδ2 T cells, suggesting for the first time that the presence of IL-4 in the tumor microenvironment would weaken the γδ T cell-mediated anti-tumor immune response by polarizing more regulatory γδ T cells.
Accumulated evidence demonstrates the opposite actions of human γδ T cells on tumors. Such contradictory functions can be explained by the plasticity and pluripotency of human γδ T cells in their tumor microenvironment. In the early stage of tumorigenesis, human γδ T cells display a crucial role of immune surveillance by recognizing tumor-related stress antigens and killing tumor cells. As the tumor grows, the skewed tumor microenvironment becomes beneficial for regulatory γδ T-cell polarization (Figure 1b) .
Human γδ T cells remain an enigmatic subset given their functional pluripotency and plasticity in different microenvironments. Although regulatory γδ T cells play an unexpected role in the inhibitory tumor microenvironment, we believe that adoptive immunotherapy using γδ T cells that are expanded and activated in vitro remains a powerful approach. To improve the anti-tumor efficacy of γδ T cell-based tumor immunotherapy, a major challenge will be understanding how to block polarization toward regulatory γδ T cells in tumor microenvironments.
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